Albert Vanderlaan

Albert Vanderlaan is a partner in Orrick’s Capital Markets Group. He works with public and private companies, SPACs, SPAC sponsors, venture capital firms and investment banks focused on the life sciences and high-growth technology sectors.

• Engagements

  Albert's engagements include:

  • TD Cowen and Stifel as joint book-running managers for the $125 million follow-on offering of Ichor Holdings, Ltd. in March 2024
  • Squadra Ventures in its Series Seed investment in Tidal Cyber in November 2023
  • Kineta, Inc. in its $3.0 million registered direct offering in October 2023
  • Squadra Ventures in its Series Seed investment in Falcomm in September 2023
  • Squadra Ventures in its Series Seed investment in Prewitt Ridge in August 2023
  • Fisker Inc. in upsizing its July 2023 0% convertible note offering to an aggregate face value offering of $1.13 billion in September 2023 
  • Fisker Inc. in its up to $680 million 0% convertible note offering in July 2023
  • CIIG Capital Partners II, a special purpose acquisition company, in its $573 million merger with Zapp Electric Vehicles in April 2023
  • Local Bounti Corporation in its loan refinancing with Cargill and sale leaseback transaction in March and April 2023, respectively
  • Kineta, Inc. in its $6.0 million registered direct offering in April 2023
  • Squadra Ventures in its Series Seed-2 investment in Net Rise in April 2023
  • Kineta, Inc. in its up to $17.5 million at-the-market offering launched in February 2023
  • Squadra Ventures in its Series Seed investment in Datalogz in February 2023
  • COVA Acquisition Corp., a SPAC sponsored by Crescent Cove Advisors and affiliates, in its business combination with ECARX Holdings, Inc. ($3.8 billion), which closed in December 2022 
  • Kineta, Inc., a clinical-stage biotechnology company developing immunotherapies, in its reverse merger with Yumanity Therapeutics, Inc., along with a $7.5 million PIPE financing, which closed in December 2022 
  • Local Bounti Corporation in its $23.3 million PIPE offering in October 2022
  • Volta Inc. in its $150 million at-the-market offering in September 2022
  • Squadra Ventures in its Series Seed investment in Primordial Labs in September 2022
  • Fisker Inc. in its up to $350 million at-the-market offering launched in May 2022
  • Local Bounti Corporation as corporate and disclosure counsel in its $122.5 million acquisition of Pete's
  • Dave Inc. in its $100 million convertible note financing in March 2022
  • Dave Inc. in its business combination with VPC Impact Acquisition Holdings III, Inc., a SPAC sponsored by Victory Park Capital ($4.0 billion), which closed in January 2022
  • Genesis Growth Tech Acquisition Corp., a special purpose acquisition company targeting companies in Europe, in its upsized $220 million initial public offering in December 2021
  • Local Bounti Corporation in its business combination with Leo Holdings III Corp, a SPAC sponsored by Lion Capital ($1.1 billion), which closed in November 2021
  • Reprise, Inc. in its $62 million Series B financing announced in November 2021
  • Volta Industries, Inc. in its business combination with Tortoise Acquisition Corp. II, a SPAC ($1.4 billion), which closed in August 2021
  • Fisker Inc. in its upsized $600 million 2.5% convertible note offering in August 2021
  • Locus in its $50 million Series C financing in June 2021
  • COVA Acquisition Corp., a special purpose acquisition company targeting companies in Southeast Asia, in its upsized $300 million initial public offering in February 2021
  • Reprise, Inc. in its $17 million Series A financing in February 2021
  • Luminar Technologies, Inc. in its business combination with Gores Metropoulos, Inc., a SPAC sponsored by affiliates of The Gores Group, LLC and Metropoulos & Co. ($3.4 billion), which closed in December 2020
  • Fisker Inc. in its business combination with Spartan Energy Acquisition Corp., a SPAC sponsored by an affiliate of Apollo Global Management, Inc. ($2.9 billion), which closed in October 2020
  • Histogenics Corporation in its reverse merger with Ocugen, Inc.*
  • ARMO BioSciences, Inc. in its acquisition by an American Pharmaceutical Company for $1.6 billion*
  • Vanda Pharmaceuticals Inc. in its $101 million follow-on public offering*
  • Synchronoss Technologies, Inc. in its sale of Intralinks Holdings, Inc. for $977 million*
  • Partner Therapeutics, Inc. in its acquisition of assets related to Leukine from sanofi-aventis U.S. LLC*
  • Synchronoss Technologies, Inc. in its acquisition of Intralinks Holdings, Inc. for $821 million*
  • REGENXBIO Inc. in its $250 million IPO*
  • Synchronoss Technologies, Inc. in its $230 million offering of 0.75% senior convertible notes*
  • Vitae Pharmaceuticals, Inc. in its acquisition by Allergan for $639 million*

  *Please note: Albert's experience includes that prior to joining Orrick.